www.tickerreport.com ·
Logicbio Therapeutics Logc to Release Quarterly Earnings on Wednesday
Topic context
This topic has been covered 280693 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedLogicBio Therapeutics is a clinical-stage genetic medicine company. The earnings release is a routine quarterly event with no new commercial mechanism or catalyst. Goldman Sachs' increased stake signals institutional interest but no immediate revenue or margin impact. The company has no approved products; LB-001 is in early trials. Commercial impact is weak and limited to the company's stock price volatility around earnings.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- LogicBio Therapeutics to release Q1 2026 earnings on May 13, 2026.
- Analysts predict a loss of $0.0409 per share.
- Goldman Sachs Group Inc. increased its stake by 284.9% in Q1, now holding ~2.00%.
- Lead product candidate LB-001 in Phase I/II trials for methylmalonic acidemia.
- Stock price $8.74, market cap $399.16M, 52-week range $6.40-$9.14.
Related stories
fool.com
Keysight Keys Q2 2026 Earnings Transcript
livemint.com
Haryana Bars Petrol Diesel Cabs for Aggregators What Means Pm Modis Austerity Push Ncrs Aqi Fuel News
dailypolitical.com
Zacks Research Weighs in on Health in Tech Fy2026 Earnings
proactiveinvestors.com.au
The Morning Catch Up Asx Set to Open Lower Ahead of Pivotal Nvidia Earnings
tickerreport.com